Straits Times Index
3,324.19 -2.09 (-0.06%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,083.94 +11.04 (+0.06%) FTSE 100
8,291.90 +44.11 (+0.53%) Bitcoin USD
61,644.95 +865.03 (+1.42%) CMC Crypto 200
1,280.41 -3.37 (-0.26%)
TRVN Jun 2024 5.000 put
| Previous close | 4.7000 |
| Open | N/A |
| Bid | 2.1500 |
| Ask | 7.0000 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 4.7000 - 4.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireTrevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in validated preclinical models TRV045 did not show a statistically significant effect in preliminary preclinical model of epileptogenesis, but results provide direction for additional NIH-initiated studies in epile
- GlobeNewswire
Trevena Reports First Quarter 2024 Results and Provides Business Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results f
- GlobeNewswire
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its
